ONC vs. QGEN: BeOne Medicines vs. Qiagen Stock Comparison

Company Profile

BeOne Medicines (ONC) and Qiagen (QGEN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ONC is classified in Biotechnology while QGEN is classified in Life Sciences Tools & Services.

Qiagen (QGEN) trades as ordinary local shares, while BeOne Medicines (ONC) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both BeOne Medicines (ONC) at 18.40% and Qiagen (QGEN) at 10.81% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Qiagen (QGEN) at 18.20% keeps the most of each sales dollar — above its industry’s net margin range — and BeOne Medicines (ONC) at 13.86% also retains a top-quartile share.

Both BeOne Medicines (ONC) at 22.15% and Qiagen (QGEN) at 27.75% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both BeOne Medicines (ONC) at 40.23% and Qiagen (QGEN) at 5.65% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Qiagen (QGEN) reports EPS growth of 409.76%, ranked against its industry; BeOne Medicines (ONC) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both BeOne Medicines (ONC) at 3.55 and Qiagen (QGEN) at 2.63 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

Both BeOne Medicines (ONC) at 0.35 and Qiagen (QGEN) at 0.47 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

BeOne Medicines (ONC) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Qiagen (QGEN) reports a yield of 0.71%, ranking against industry peers normally.

BeOne Medicines (ONC) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Qiagen (QGEN) reports a payout of 18.21%, ranking against industry peers normally.

Dividend Metrics

Valuation

Qiagen (QGEN) at 27.21 is near its industry’s usual P/E ratio, while BeOne Medicines (ONC) at 52.17 sits in the richer quartile — ONC needs stronger growth or earnings quality to justify the premium.

On P/S ratio, both BeOne Medicines (ONC) at 7.04 and Qiagen (QGEN) at 4.91 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Qiagen (QGEN) at 2.99 is valued about in line with its industry on P/B ratio, while BeOne Medicines (ONC) at 7.98 carries an above-peer premium to book — ONC is pricier on assets.

Valuation Metrics